Forbion Capital Partners has closed its third main fund at $208m, attracting commitments from Charles River Laboratories, Knight Therapeutics and unnamed insurance providers.

Laboratory services provider Charles River Laboratories and pharmaceutical firm Knight Therapeutics are among the limited partners for a €183m ($208m) fund closed yesterday by Netherlands-based, life sciences-focused venture capital firm Forbion Capital Partners.

Forbion Capital Fund III (FCF III) also attracted KfW, European Investment Fund and Dutch Venture Initiative, as well as undisclosed insurance companies, Europe-based family offices, regional investment agencies and pension funds.

FCF III will follow a similar strategy to the firm’s last fund, allocating approximately 70% of…